Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

Reviva Pharmaceuticals Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CUPERTINO, CALIF., JUNE 23, 2026 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT LAXMINARAYAN BHAT, PHD.

REVIVA PHARMACEUTICALS TO PRESENT AT THE LIFE SCIENCES INVESTOR FORUM ON JUNE 24TH

CUPERTINO, CALIF., MAY 18, 2026 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (OTCQB: RVPH) (REVIVA, THE COMPANY WE OR US), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT LAXMINARAYAN BHAT, PHD, FOUNDER, PRESIDENT, AND CEO OF REVIVA, WILL PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST JIM MOLLOY AT A.G.P.

REVIVA TO PARTICIPATE IN FIRESIDE CHAT AT A.G.P.'S ANNUAL HEALTHCARE COMPANY SHOWCASE

- COMPOSITION OF MATTER PROVISIONAL PATENT APPLICATION FILED FOR A NEW FORM OF BRILAROXAZINE DESIGNED TO EXTEND PATENT LIFE AND COMMERCIAL EXCLUSIVITY THROUGH 2046 - - FDA FEEDBACK ON USE OF NEW FORM OF BRILAROXAZINE IN THE RECOVER-2 TRIAL AND FUTURE NDA EXPECTED IN MID-2026 - - INITIATION OF PATIENT ENROLLMENT IN RECOVER-2 REGISTRATIONAL PHASE 3 TRIAL EXPECTED Q3 2026 -

REVIVA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

- WRITTEN FDA RECOMMENDATIONS INCLUDE A SECOND PHASE 3 TRIAL TO GENERATE ADDITIONAL EFFICACY AND SAFETY DATA PRIOR TO NDA SUBMISSION OF BRILAROXAZINE FOR SCHIZOPHRENIA 

REVIVA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

CUPERTINO, CALIF., MARCH 18, 2026 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING WITH HEALTHCARE FOCUSED INSTITUTIONAL INVESTORS FOR THE PURCHASE AND SALE OF 6,666,667 SHARES OF ITS COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) TOGETHER WITH SERIES G WARRANTS TO PURCHASE UP TO 6,666,667 SHARES OF COMMON STOCK (THE "SERIES G WARRANTS") AND SERIES H WARRANTS TO PURCHASE UP TO 6,666,667 SHARES OF COMMON STOCK (THE "SERIES H WARRANTS"), AT A COMBINED OFFERING PRICE OF $1.50 PER SHARE AND ACCOMPANYING WARRANTS, FOR AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $10 MILLION BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER OFFERING EXPENSES.

REVIVA PHARMACEUTICALS HOLDINGS, INC. ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING

CUPERTINO, CALIF., MARCH 18, 2026 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT IT INTENDS TO OFFER SHARES OF ITS COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK IN A PUBLIC OFFERING. ALL OF THE SECURITIES TO BE SOLD IN THE OFFERING ARE TO BE OFFERED BY REVIVA. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

REVIVA PHARMACEUTICALS HOLDINGS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING

CUPERTINO, CALIF., DEC. 29, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED LAXMINARAYAN BHAT, PH.D., FOUNDER, PRESIDENT, AND CEO OF REVIVA WILL PRESENT AT THE SACHS 9TH ANNUAL NEUROSCIENCE INNOVATION FORUM, TAKING PLACE JANUARY 11, 2026, IN SAN FRANCISCO, CA.

REVIVA TO PRESENT AT THE SACHS 9TH ANNUAL NEUROSCIENCE INNOVATION FORUM

WRITTEN FEEDBACK FROM FDA PRE-NDA MEETING INCLUDES A RECOMMENDATION TO CONDUCT A SECOND PHASE 3 TRIAL TO GENERATE ADDITIONAL EFFICACY AND SAFETY DATA PRIOR TO NDA SUBMISSION OF BRILAROXAZINE FOR THE TREATMENT OF SCHIZOPHRENIA

REVIVA ANNOUNCES REGULATORY UPDATE REGARDING THE DEVELOPMENT OF BRILAROXAZINE FOR THE TREATMENT OF SCHIZOPHRENIA

 PRE-NDA MEETING WITH FDA TO DISCUSS BRILAROXAZINE'S PATH TO APPROVAL FOR SCHIZOPHRENIA PLANNED IN Q4 2025   POTENTIAL NDA SUBMISSION FOR SCHIZOPHRENIA INDICATION TARGETED FOR Q2 2026   EUROPEAN PATENT GRANTED COVERING USE OF BRILAROXAZINE FOR THE TREATMENT OF PULMONARY FIBROSIS ADDS TO EXISTING PATENT PROTECTION IN KEY GLOBAL MARKETS  CUPERTINO, CALIF., NOV. 13, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 AND SUMMARIZED RECENT BUSINESS HIGHLIGHTS.

REVIVA REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

CUPERTINO, CALIF., OCT. 28, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT NEGATIVE SYMPTOM DATA FOR BRILAROXAZINE FROM THE PHASE 3 RECOVER DOUBLE-BLIND TRIAL IN PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA, AND FROM THE LONG-TERM OPEN-LABEL EXTENSION TRIAL IN CLINICALLY STABLE SCHIZOPHRENIA PATIENTS WILL BE PRESENTED AS A POSTER PRESENTATION AT THE CNS SUMMIT 2025, TAKING PLACE NOVEMBER 2-5, IN BOSTON, MASSACHUSETTS.

REVIVA TO PRESENT NEGATIVE SYMPTOM DATA FOR BRILAROXAZINE IN SCHIZOPHRENIA FROM THE PHASE 3 RECOVER DOUBLE-BLIND AND OPEN-LABEL EXTENSION TRIALS AT THE CNS SUMMIT 2025

Reviva Pharmaceuticals Holdings, Inc.

RVPH

Price

Financial Reports

No items found.

Press Releases

Reviva Pharmaceuticals Holdings, Inc.

RVPH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RVPH